RxDoctor Payments Data

Kim Nguyen, MD

Internal Medicine · Chattanooga, TNNPI 1194005439

Payments from drug & device makers

$7,169in general payments, 2019–2025

Across 458 payments — averaging $15.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$842
  • Pfizer$735
  • Amgen$621
  • GSK$480
  • Astellas Pharma US Inc$476
  • AbbVie$385
  • plus $4K from 39 others

What the payments were for

  • Food & beverage$7,09099%
  • Education$791%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$7,169 in reported general payments places this provider in the 90th percentile of 2,216 internal medicine providers in Tennessee.

See all internal medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$165,194
Medicare patients
343
Services billed
3,346

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin124$114,096
OzempicSemaglutide82$107,662
MounjaroTirzepatide85$101,757
FarxigaDapagliflozin Propanediol112$85,520
EliquisApixaban96$78,892
Trelegy ElliptaFluticasone/Umeclidin/Vilanter70$56,074
Tresiba Flextouch U-100Insulin Degludec47$34,858
TrulicityDulaglutide32$33,350
RybelsusSemaglutide26$29,927
XareltoRivaroxaban19$26,074
Breo ElliptaFluticasone/Vilanterol40$23,030
LinzessLinaclotide21$22,278
CreonLipase/Protease/Amylase17$19,998
MyrbetriqMirabegron25$11,910
Novolog FlexpenInsulin Aspart29$6,635

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$842$137,588108 claims
Lilly USA, LLCMounjaro, Trulicity$255$135,106117 claims
Boehringer IngelheimJardiance$76$114,096124 claims
AstraZenecaFarxiga$266$85,520112 claims
PfizerEliquis, Paxlovid$735$80,322126 claims
GSKTrelegy Ellipta, Breo Ellipta$480$79,104110 claims
AbbVieLinzess, Creon, Synthroid$385$44,22273 claims
Johnson & JohnsonXarelto$282$26,07419 claims
Astellas Pharma US IncMyrbetriq$476$11,91025 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,216 internal medicine providers in Tennessee.

Other internal medicine in Chattanooga

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →